Latest Strategic Review News

PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.

FortifAI Limited reported a 15% decline in game revenue to $4.3 million for FY2025 but achieved a significant 72% reduction in net loss to $1.99 million, supported by operational cost cuts and a $3.6 million capital raise.

CI1 reported a sharp 57% revenue decline in FY25 but reduced its comprehensive loss by 64% through strategic disposals and capital returns. The company’s financial services operations in Australia and Singapore faced tough market conditions, prompting a portfolio reshaping.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Resimac Group reported a 13% rise in operating profit for FY25, driven by strong asset growth and a major auto finance acquisition, while declaring a total dividend of 19 cents per share.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

Perpetual Limited reported a steady underlying profit for FY25, achieving significant cost savings while navigating asset management outflows and advancing the sale of its Wealth Management division.

Ramsay Health Care posted solid revenue growth driven by its Australian and UK hospital businesses, despite a significant impairment charge impacting net profit. The group advances a multi-year transformation focusing on operational efficiency and capital discipline.

Ramsay Health Care reported a 6.8% revenue increase and a modest rise in underlying profit for FY25, despite a significant impairment in its UK mental health division. The company maintains a strong dividend and outlines a cautiously optimistic outlook for FY26.

Urbanise.com Limited reported a 4.2% revenue increase and a 77% improvement in adjusted EBITDA loss for FY2025, driven by new contracts and a key partnership with NAB. The company ended the year cash flow positive with a strong balance sheet, setting the stage for a transformative product launch in 2026.

Xref Limited reported a significantly reduced net loss for FY2025 and a return to positive EBITDA, driven by strategic cost restructuring and a transition to a SaaS business model.

Aquirian Limited reported a 13% revenue increase to $26.1 million in FY25, securing a $20 million three-year contract with a Western Australian goldmine and advancing its innovative Collar Keeper® technology.